Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 7/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5382431 | 0.99 | MAPK14 (0.50) | MAPK14GSK3BMKNK1CSNK1DMAPK13 | |
| SCHEMBL5382297 | 0.96 | MAPK14 (0.46) | MAPK14GSK3BMKNK1 | |
| SCHEMBL5395033 | 0.95 | MAPK14 (0.46) | MAPK14GSK3BMKNK1 | |
| SCHEMBL5398417 | 0.95 | MAPK14 (0.46) | MAPK14GSK3BMKNK1 | |
| SCHEMBL14593041 | 0.94 | MKNK1 (0.49) | MAPK14GSK3BMKNK1MAPK13MAPK12 | |
| SCHEMBL5382150 | 0.93 | MAPK14 (0.49) | MAPK14GSK3BMKNK1 | |
| SCHEMBL5379217 | 0.93 | MKNK1 (0.49) | MAPK14GSK3BMKNK1CSNK1DMAPK13 | |
| SCHEMBL5394953 | 0.90 | MKNK1 (0.52) | MAPK14GSK3BMKNK1 | |
| SCHEMBL5382444 | 0.89 | GSK3B (0.39) | MAPK14GSK3BMKNK1 | |
| SCHEMBL5384542 | 0.89 | MAPK14 (0.48) | MAPK14GSK3BMKNK1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-1311507-B1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| EP-1311507-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016359-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | RAF1, SBK3, MAP3K3 | MAPK14 77/4885GSK3B 326/4885MKNK1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.